Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer

Cyclin-dependent kinases 4/6 (CDK4/6) inhibitors such as palbociclib are approved for the treatment of metastatic estrogen receptor–positive (ER(+)) breast cancer in combination with endocrine therapies and significantly improve outcomes in patients with this disease. However, given the large number...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yu-Chen, Stein, Shayna, Nardone, Agostina, Liu, Weihan, Ma, Wen, Cohen, Gabriella, Guarducci, Cristina, McDonald, Thomas O., Jeselsohn, Rinath, Michor, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652811/
https://www.ncbi.nlm.nih.gov/pubmed/37921419
http://dx.doi.org/10.1158/2767-9764.CRC-23-0257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652811/
https://www.ncbi.nlm.nih.gov/pubmed/37921419
http://dx.doi.org/10.1158/2767-9764.CRC-23-0257

Ejemplares similares